ONCOLOGIC OUTCOMES OF RADICAL PROSTATECTOMY AND PROGNOSTIC STRATIFICATION IN PATIENTS WITH CLINICALLY LOCALLY ADVANCED PROSTATE CANCER

  • Sergiy Vozianov State Institution "Institute of Urology of National Academy of Medical Sciences of Ukraine", Ukraine
  • Viacheslav Grygorenko State Institution "Institute of Urology of National Academy of Medical Sciences of Ukraine", Ukraine
  • Mark Vikarchuk State Institution "Institute of Urology of National Academy of Medical Sciences of Ukraine", Ukraine
  • Rostislav Danylets State Institution "Institute of Urology of National Academy of Medical Sciences of Ukraine", Ukraine
  • Oleksandr Banas State Institution "Institute of Urology of National Academy of Medical Sciences of Ukraine", Ukraine
  • Nataliia Brovko State Institution "Institute of Urology of National Academy of Medical Sciences of Ukraine", Ukraine
  • Serhii Volkov State Institution "Institute of Urology of National Academy of Medical Sciences of Ukraine", Ukraine
Keywords: locally-advanced prostate cancer, prognostic stratification

Abstract

Oncologic outcomes of radical prostatectomy in 106 patients with clinically locally advanced prostate cancer were demonstrated. The mean follow-up was 50.6 (12-129) months. 5-year recurrence-free survival was 47.7 %, 5-year cancer-specific and overall survival - 85.8 %. Patients were devided into three different risk groups: low risk patients had PSA level <20 ng/ml, biopsy Gleason score ≤6 and absence of the seminal vesicle invasion of cancer; intermediate risk was noted when the patient had only one of poor prognostic factors (PSA ≥20 ng/ml or biopsy Gleason score≥7 or presence of cancer invasion to the seminal vesicle) and high risk patients had 2 or 3 poor prognostic factors. For patients of  low, intermediate and high risk the biochemical reccurence rates were 14.3 %, 37.1 % and 70.2 %, respectively (p=0.002). The patients of intermediate and high risk had clinically significant higher risk of biochemical reccurence than those of low risk with odds ratio 3.0 and 8.5, respectively. Such grouping may help in guiding the individualized treatment for these patients.

Downloads

Download data is not yet available.

References

Gnanapragasam, V. J., Mason, M. D., Shaw, G. L., Neal, D. E. (2011). The role of surgery in high-risk localised prostate cancer. BJU International, 109 (5), 648–658. doi: 10.1111/j.1464-410x.2011.10596.x

Van den Ouden, D., Schroder, F. H. (2000). Management of locally advanced prostate cancer. World Journal of Urology, 18 (3), 194–203. doi: 10.1007/s003459900102

Fedorenko, Z. P., Goulak, L. O., Gorokh, Y. L. et. al. (2004). Cancer in Ukraine, 2002–2003. Bulletin of national cancer registry of Ukraine. Kyiv-2004, 43.

Fedorenko, Z. P., Goulak, L. O., Gorokh, Y. L. et. al. (2015). Cancer in Ukraine, 2013–2014. Bulletin of national cancer registry of Ukraine. Kyiv-2015, 48–49.

NCCN guidelines on prostate cancer, version 1. (2016). National Comprehensive Cancer Network Website. Available at: http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf

Wiegel, T., Bottke, D., Steiner, U., Siegmann, A., Golz, R., Storkel, S. et. al. (2009). Phase III Postoperative Adjuvant Radiotherapy After Radical Prostatectomy Compared With Radical Prostatectomy Alone in pT3 Prostate Cancer With Postoperative Undetectable Prostate-Specific Antigen: ARO 96-02/AUO AP 09/95. Journal of Clinical Oncology, 27 (18), 2924–2930. doi: 10.1200/jco.2008.18.9563

Dorff, T. B., Flaig, T. W., Tangen, C. M., Hussain, M. H. A., Swanson, G. P., Wood, D. P. et. al. (2011). Adjuvant Androgen Deprivation for High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921 Study. Journal of Clinical Oncology, 29 (15), 2040–2045. doi: 10.1200/jco.2010.32.2776

Yossepowitch, O., Eggener, S. E., Serio, A. M., Carver, B. S., Bianco, F. J., Scardino, P. T., Eastham, J. A. (2008). Secondary Therapy, Metastatic Progression, and Cancer-Specific Mortality in Men with Clinically High-Risk Prostate Cancer Treated with Radical Prostatectomy. European Urology, 53 (5), 950–959. doi: 10.1016/j.eururo.2007.10.008

Carver, B. S., Bianco, F. J., Scardino, P. T., Eastham, J. A. (2006). Long-Term Outcome Following Radical Prostatectomy in Men With Clinical Stage T3 Prostate Cancer. The Journal of Urology, 176 (2), 564–568. doi: 10.1016/j.juro.2006.03.093

Sobin, L. H., Gospodarowicz, M. K., Wittekind, Ch. (2010). International Union against Cancer. 7th ed. 2009. Chichester; New Jersey: Wiley-Blackwell, 243–248.

Ward, J. F., Slezak, J. M., Blute, M. L., Bergstralh, E. J., Zincke, H. (2005). Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. BJU International, 95 (6), 751–756. doi: 10.1111/j.1464-410x.2005.05394.x

Carver, B. S., Bianco, F. J., Scardino, P. T., Eastham, J. A. (2006). Long-Term Outcome Following Radical Prostatectomy in Men With Clinical Stage T3 Prostate Cancer. The Journal of Urology, 176 (2), 564–568. doi: 10.1016/j.juro.2006.03.093

Hakenberg, O. W., Frohner, M., Wirth, M. P. (2006). Treatment of Locally Advanced Prostate Cancer – The Case for Radical Prostatectomy. Urologia Internationalis, 77 (3), 193–199. doi: 10.1159/000094808

Van Poppel, H., Joniau, S., Haustermans, K. (2007). Surgery alone for advanced prostate cancer? European Journal of Cancer Supplements, 5 (5), 157–169. doi: 10.1016/s1359-6349(07)70036-8

Van Poppel, H., Goethuys, H., Callewaert, P., Vanuytsel, L., Van de Voorde, W., Baert, L. (2000). Radical Prostatectomy Can Provide a Cure For Well–Selected Clinical Stage T3 Prostate Cancer. European Urology, 38 (4), 372–379. doi: 10.1159/000020311

Gontero, P., Marchioro, G., Pisani, R., Zaramella, S., Sogni, F., Kocjancic, E. et. al. (2007). Is Radical Prostatectomy Feasible in All Cases of Locally Advanced Non-Bone Metastatic Prostate Cancer? Results of a Single-Institution Study. European Urology, 51 (4), 922–930. doi: 10.1016/j.eururo.2006.08.050

Xylinas, E., Dache, A., Roupret, M. (2010). Is radical prostatectomy a viable therapeutic option in clinically locally advanced (cT3) prostate cancer? BJU International, 106 (11), 1596–1600. doi: 10.1111/j.1464-410x.2010.09630.x

D’Amico, A. V., Whittington, R., Malkowicz, S. B., Schultz, D., Blank, K., Broderick, G. A. et. al. (1998). Biochemical Outcome After Radical Prostatectomy, External Beam Radiation Therapy, or Interstitial Radiation Therapy for Clinically Localized Prostate Cancer. JAMA, 280 (11), 969–974. doi: 10.1001/jama.280.11.969

Yossepowitch, O., Eggener, S. E., Bianco, F. J., Carver, B. S., Serio, A., Scardino, P. T., Eastham, J. A. (2007). Radical Prostatectomy for Clinically Localized, High Risk Prostate Cancer: Critical Analysis of Risk Assessment Methods. The Journal of Urology, 178 (2), 493–499. doi: 10.1016/j.juro.2007.03.105

D’Amico, A. V., Moul, J., Carroll, P. R., Sun, L., Lubeck, D., Chen, M.-H. (2003). Cancer-Specific Mortality After Surgery or Radiation for Patients With Clinically Localized Prostate Cancer Managed During the Prostate-Specific Antigen Era. Journal of Clinical Oncology, 21 (11), 2163–2172. doi: 10.1200/jco.2003.01.075


👁 375
⬇ 263
Published
2017-03-31
How to Cite
Vozianov, S., Grygorenko, V., Vikarchuk, M., Danylets, R., Banas, O., Brovko, N., & Volkov, S. (2017). ONCOLOGIC OUTCOMES OF RADICAL PROSTATECTOMY AND PROGNOSTIC STRATIFICATION IN PATIENTS WITH CLINICALLY LOCALLY ADVANCED PROSTATE CANCER. EUREKA: Health Sciences, (2), 30-37. https://doi.org/10.21303/2504-5679.2017.00314
Section
Medicine and Dentistry